Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma

Bromodomain and extraterminal (BET) proteins are transcriptional activators for multiple oncogenic processes in diffuse large B-cell lymphoma (DLBCL), including MYC, BCL2, E2F, and toll-like receptor signaling. We report results of a phase 1b dose-escalation study of the novel, subcutaneous BET inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickinson, Michael, Briones, Javier, Herrera, Alex F., González-Barca, Eva, Ghosh, Nilanjan, Cordoba, Raul, Rutherford, Sarah C., Bournazou, Eirini, Labriola-Tompkins, Emily, Franjkovic, Izolda, Chesne, Evelyne, Brouwer-Visser, Jurriaan, Lechner, Katharina, Brennan, Barbara, Nüesch, Eveline, DeMario, Mark, Rüttinger, Dominik, Kornacker, Martin, Hutchings, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759125/
https://www.ncbi.nlm.nih.gov/pubmed/34581757
http://dx.doi.org/10.1182/bloodadvances.2021004619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759125/
https://www.ncbi.nlm.nih.gov/pubmed/34581757
http://dx.doi.org/10.1182/bloodadvances.2021004619

Ejemplares similares